News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Yüksel Ürün: MFS continues to be a reliable predictor for overall survival
Photo from Yüksel Ürün/X
Dec 10, 2023, 16:59

Yüksel Ürün: MFS continues to be a reliable predictor for overall survival

Yüksel Ürün, Medical Oncologist at Ankara University, shared on X:

“With better access to docetaxel and other treatments for advanced prostate cancer, MFS continues to be a reliable predictor for overall survival. This reinforces MFS’s role as the main outcome for current adjuvant trials in localized prostate cancer, impacting future trial designs.”

For more details click here.
Source: Yüksel Ürün/X

access to treatment adjuvant trials advanced disease cancer docetaxel localized disease MFS OncoDaily Oncology overall survival prostate cancer trial designs Yüksel Ürün
Special Coverage
Blog
Jun 19, 2025, 17:36
ESTRO Introduces KAYAC+ to Advance Radiation Therapy For Adolescents And Young Adults With Cancer
Blog
Jun 19, 2025, 17:26
XVII CCI LATAM Conference Was a Celebration Of a Growing Community, Unity, and Hope - Childhood Cancer International
Blog
Jun 19, 2025, 17:07
Join The AI For Everyone, Everywhere, Let’s talk about Large Language Models Meeting - SIOP
Blog
Jun 19, 2025, 16:57
David Planchard: We Need to Work Together to Develop The Wave of New Treatments That Is Coming For Our Patients
Blog
Jun 19, 2025, 16:21
Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma
Blog
Jun 19, 2025, 15:15
Antonio Jimenez Jimenez Shared Findings from the Multicenter ACCESS trial, Supported by CIBMTR and NMDP